Scandinavian Journal of Infectious Diseases · 1995 · 48 citations · 21 references
PharmacyInfectious DiseasesPharmacotherapyAntimicrobial PharmacotherapyInfectious Disease PharmacotherapyMedical MicrobiologyAntibacterial TherapyAntimicrobial DosingAntimicrobial TherapyCommunity-acquired Infection TreatmentEmpiric Antimicrobial TherapyPneumonia PharmacotherapyClinical Trial Efficacy EvaluationCommunity-acquired Pneumonia TreatmentLegionella InfectionLegionella Pneumonia TreatmentLegionnaires' DiseasePneumonia Antibiotic TherapyTissue EosinophiliaTotal Dose
A clinical, retrospective and non-comparative study was undertaken to assess the clinical efficacy and tolerability of azithromycin in the treatment of community-acquired pneumonia caused by Legionella pneumophila. A total of 16 patients with a serologically confirmed diagnosis of Legionnaires' diseases were included. Azithromycin was administered orally at a total dose of 1.5 g for either 3 or 5 days. All patients were no side-effects requiring discontinuation of the treatment. Further increase of abnormal baseline liver function was recorded in 2 patients and in 1 patient mild, transient eosinophilia. Equal clinical efficacy and tolerability were observed with the 3- and 5-day dosage regimen. These results indicate that azithromycin given at a standard dose of 1.5 g is effective and well tolerated in the treatment of Legionnaires' disease.
21
HOSPITAL STUDY OF ADULT COMMUNITY-ACQUIRED PNEUMONIA
J T Macfarlane, M.J. Ward, R. Finch et al. · The Lancet · 1982 · 475 citations
Azithromycin concentrations at the sites of pulmonary infection
Robert A. Wise, J. M. Andrews, J. P. Ashby et al. · European Respiratory Journal · 1990 · 198 citations